

KERYX BIOPHARMACEUTICALS INC
Form 8-K
November 19, 2003

=====

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 18, 2003

Keryx Biopharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware	000-30929	13-4087132
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

750 Lexington Avenue
New York, New York 10022
(Address of principal executive offices)

(212)-531-5965
(Registrant's telephone number, including area code)

=====

Item 5. Other Events

On November 18, 2003 Keryx Biopharmaceuticals, Inc. announced the private placement of approximately 3.5 million shares of its common stock and warrants to purchase an additional 705,000 shares of common stock. The November 18, 2003 Press Release relating to the private placement is incorporated herein by reference and is attached hereto as Exhibit 99.1.

Item 7. Financial Statements and Exhibits.

(c) Exhibits

The following exhibit is filed as a part of this report:

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

Exhibit Number -----	Description -----
99.1	Press Release dated November 18, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Keryx Biopharmaceuticals, Inc.
(Registrant)

Date: November 18, 2003

By: /s/ Michael S. Weiss

Michael S. Weiss
Chairman and Chief Executive Officer